Population pharmacokinetics and pharmacodynamics of tosufloxacin granules in pediatric infectious diseases

Japanese Journal of Chemotherapy

Volumn 58, Issue SUPPL. 2, 2010, Pages 69-77

  Sunakawa, Keisuke ^a   Iwai, Naoichi ^b   Iwata, Satoshi ^c   Ouchi, Kazunobu ^d   Sakata, Hiroshi ^e   Suzuki, Kenji ^f   Iino, Yukiko ^g   Taiji, Hidenobu ^h   Kudo, Fumiyo ⁱ   Nozawa, Kenji ^j  

^a KITASATO UNIVERSITY   (Japan)

^b Meitetsu Hospital   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KAWASAKI MEDICAL SCHOOL   (Japan)

^e Asahikawa Kosei General Hospital   (Japan)

^f FUJITA HEALTH UNIVERSITY   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

ⁱ CHIBA PREFECTURAL UNIVERSITY OF HEALTH SCIENCES   (Japan)

^j TOYAMA CHEMICAL CO LTD   (Japan)

more..

Author keywords

Child; Dose finding; PK PD; Population pharmacokinetics; Tosufloxacin

Indexed keywords

TOSUFLOXACIN TOSILATE;

ACUTE OTITIS MEDIA; ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL PNEUMONIA; BODY WEIGHT; CHILD; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG GRANULE; HAEMOPHILUS INFLUENZAE; HUMAN; INFANT; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRESCHOOL CHILD; SCHOOL CHILD; STREPTOCOCCUS PNEUMONIAE;

EID: 78649413798     PISSN: 13407007     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Beal S L, Sheiner L B: NONMEM user's guide. NONMEM Project Group, University of California, San Francisco, 1992
2. SAS/STAT User's Guide. SAS Institute Inc. Cary, NC, 2000
3. Mouton J W: Impact of pharmacodynamics on breakpoint selection for susceptibility testing. Infect Dis Clin North Am 2003; 17: 579-98
4. International Conference on Harmonisation Harmonised Tripartite Guidelines. 2000. Clinical investigation of medical products in the pediatric population. http://www.fdagov/oc/gcp/draft.html
5. Scheld W M: Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 2003; 9: 1-9 (Pubitemid 36110195)
6. Craig W A: Does the dose matter? Clin Infect Dis 2001; 33 (S-3): S233-7
7. Craig W A: The role of pharmacodynamics in effective treatment of community-acquired pathogens. Advanced Studies in Medicine 2002; 2: 126-34
8. Homma T, Hori T, Sugimori G, Yamano Y: Pharmacodynamic assessment based on mutant prevention concentrations of fluoroquinolones to prevent the emergence of resistant mutant of Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 3810-5 (Pubitemid 350057775)